Regenesis Biomedical, Inc.
12
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
25.0%
3 terminated/withdrawn out of 12 trials
72.7%
-13.8% vs industry average
0%
0 trials in Phase 3/4
125%
10 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy
Role: lead
An Open-Label Trial of PEMF Therapy [Provant Infinity Therapy System] for Home Use in Postoperative Pain
Role: lead
A Registry Study to Evaluate Outcomes of PEMF Therapy in Subjects With Various Pain Etiologies
Role: lead
Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy
Role: lead
Nociceptive Pain Fiber Response
Role: lead
Proof of Concept Study of PEMF (Pulsed Electromagnetic Field) Therapy in Subjects With Osteoarthritis of the Knee
Role: lead
Pilot Study of PEMF Therapy in Treatment of Post-operative Pain Following Total Knee Arthroplasty
Role: lead
Pulsed Radiofrequency Energy to Treat Post-Bunionectomy Pain
Role: lead
A Study to Evaluate PEMF Therapy on Experimentally Inducted Pain in Subjects With Painful Peripheral Diabetic Neuropathy
Role: lead
Study of PEMF (Pulsed Electromagnetic Field) Therapy in the Treatment of Persistent Post-Operative Pain Following Lumbar Surgery
Role: lead
A Pilot Study of the Provant Therapy System in Subjects With Diabetic Foot Ulcers
Role: lead
Provant Therapy of Venous Stasis Ulcer Trial
Role: collaborator
All 12 trials loaded